Radiopharm to present at NWR healthcare event

Radiopharm Theranostics Limited, a clinical-stage radiopharmaceutical company, will present at the NWR Virtual Healthcare Conference.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

Radiopharm Theranostics Limited, a clinical-stage radiopharmaceutical company, will present at the NWR Virtual Healthcare Conference. CEO & Managing Director Riccardo Canevari is scheduled to present at 8:30am AEDT on Wednesday, 25 March 2026, via online webinar.

Shareholders, investors and other interested parties can register through the provided Zoom link, with a recording available shortly after the live session. The replay will also be accessible on the company’s website and social media. The filing also reiterates that Radiopharm is listed on ASX (RAD) and NASDAQ (RADX) and outlines its oncology-focused development pipeline.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Radiopharm Theranostics (RADX) disclose in this Form 6-K?

Radiopharm Theranostics disclosed that it will present at the NWR Virtual Healthcare Conference. The filing attaches the related Australian Securities Exchange announcement and provides details on the presentation timing, registration link, replay access, and key company background as a clinical-stage oncology radiopharmaceutical developer.

When will Radiopharm Theranostics (RADX) present at the NWR Virtual Healthcare Conference?

Radiopharm Theranostics’ CEO and Managing Director Riccardo Canevari will present at 8:30am AEDT on Wednesday, 25 March 2026. The session is part of the NWR Virtual Healthcare Conference and will be delivered online, with both live access and a recording available for interested investors and stakeholders.

How can investors attend the Radiopharm Theranostics (RADX) NWR conference presentation?

Investors can attend by registering through the specified Zoom webinar link included in the announcement. After the live presentation, a recording will remain available at the same link, and the replay will also be posted on Radiopharm Theranostics’ corporate website and social media channels for ongoing access.

What type of company is Radiopharm Theranostics (RADX) according to the filing?

Radiopharm Theranostics is described as a clinical-stage radiotherapeutics company developing radiopharmaceutical products for diagnostic and therapeutic use in oncology. Its pipeline spans peptides, small molecules and monoclonal antibodies, with one Phase 2 and four Phase 1 trials in solid tumors such as lung, breast and brain metastases.

On which exchanges are Radiopharm Theranostics (RADX) shares listed?

Radiopharm Theranostics shares are listed on the Australian Securities Exchange under ticker RAD and on NASDAQ under ticker RADX. This dual listing supports access to both Australian and U.S. capital markets as the company advances its pipeline of radiopharmaceutical candidates targeting areas of high unmet medical need.

Will the NWR conference presentation replay for Radiopharm Theranostics (RADX) be available?

Yes. A recording of the Radiopharm Theranostics presentation will be available shortly after the live NWR Virtual Healthcare Conference session. The replay can be accessed via the original Zoom registration link and will also be posted on the company’s website and social media profiles for later viewing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/19/2026 - 06:22 AM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of March 2026

Commission File Number: 001-41621

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

RADIOPHARM THERANOSTICS LIMITED

EXPLANATORY NOTE

Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on March 19, 2026 titled:

“RAD to present at NWR Virtual Healthcare Conference”

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

EXHIBITS

Exhibit Number		Description
99.1		RAD to present at NWR Virtual Healthcare Conference

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	RADIOPHARM THERANOSTICS LIMITED

Date: March 19, 2026	By:	/s/ Phillip Hains
		Phillip Hains
		Company Secretary

Exhibit 99.1

ASX ANNOUNCEMENT
19 March 2026

Radiopharm to present at NWR Virtual Healthcare Conference

Sydney, Australia– 19 March 2026 – Radiopharm Theranostics (ASX: RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that it will present at the NWR Virtual Healthcare Conference.

CEO & Managing Director Riccardo Canevari will present at 8:30am AEDT on Wednesday 25 March 2026.

Shareholders, investors and interested parties are encouraged to register to attend the presentation at the following link: https://us02web.zoom.us/webinar/register/WN_WlOvxNAQRImgmoTV07BUsA

A recording will be available at the above link shortly after the conclusion of the live session, and the replay will also be available via the Company’s website and social media channels.

Questions can be submitted on the day or sent in advance to matt@nwrcommunications.com.au

For more information please visit: https://nwrcommunications.com/healthconf

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and four Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com.

Authorised on behalf of the Radiopharm Theranostics board of directors by Chairman Paul Hopper.

For more information:

Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889

ASX ANNOUNCEMENT
19 March 2026

Anne Marie Fields

Precision AQ (Formerly Stern IR)

E: annemarie.fields@precisionaq.com

Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases

EX-99.1 RAD TO PRESENT AT NWR VIRTUAL HEALTHCARE CONFERENCE 7.7 KB